CONTEXT: Alzheimer disease (AD) susceptibility genes have been identified on chromosomes 1, 14, 19, and 21, and a recent study has suggested a locus on chromosome 12. OBJECTIVE: To confirm or refute the existence of a familial AD susceptibility locus on chromosome 12 in an independent sample of familial AD cases. DESIGN: Retrospective cohort study. DNA data for 6 chromosome 12 genetic markers were evaluated using parametric lod score and nonparametric linkage methods and linkage heterogeneity tests. The latter include the admixture test of homogeneity in the total group of families and the predivided sample test in families stratified by the presence or absence of an apolipoprotein E (APOE) epsilon4 allele among affected members. Parametric analyses were repeated assuming autosomal dominant inheritance of AD and either age- and sex-dependent penetrance or zero penetrance for the analysis of unaffected relatives. SETTING: Clinical populations in the continental United States, Canada, Argentina, and Italy. PATIENTS: Fifty-three white families composed of multiple members affected with AD, from whom DNA samples were obtained from 173 patients with AD whose conditions were diagnosed using established criteria and from 146 nondemented relatives. MAIN OUTCOME MEASURE: Presence of an APOE epsilon4 allele among affected family members. RESULTS: Using parametric methods, no evidence for linkage to the region spanned by the chromosome 12 markers could be detected if familial AD is assumed to arise from the same genetic locus in all 53 families. However, significant evidence for linkage was detected in the presence of locus heterogeneity using the admixture test (odds ratio, 15, 135:1). The estimated proportion of linked families within the 53 families examined varied between 0.40 and 0.65, depending on the genetic model assumed and APOE status. The precise location of the AD gene could not be determined, but includes the entire region suggested previously. Nonparametric linkage analysis confirmed linkage to chromosome 12 with the strongest evidence at D12S96 (P<.001). CONCLUSIONS: Our data provide independent confirmation of the existence of an AD susceptibility locus on chromosome 12 and suggest the existence of AD susceptibility genes on other chromosomes. Screening a larger set of families with additional chromosome markers will be necessary for identifying the chromosome 12 AD gene.
CONTEXT: Alzheimer disease (AD) susceptibility genes have been identified on chromosomes 1, 14, 19, and 21, and a recent study has suggested a locus on chromosome 12. OBJECTIVE: To confirm or refute the existence of a familial AD susceptibility locus on chromosome 12 in an independent sample of familial AD cases. DESIGN: Retrospective cohort study. DNA data for 6 chromosome 12 genetic markers were evaluated using parametric lod score and nonparametric linkage methods and linkage heterogeneity tests. The latter include the admixture test of homogeneity in the total group of families and the predivided sample test in families stratified by the presence or absence of an apolipoprotein E (APOE) epsilon4 allele among affected members. Parametric analyses were repeated assuming autosomal dominant inheritance of AD and either age- and sex-dependent penetrance or zero penetrance for the analysis of unaffected relatives. SETTING: Clinical populations in the continental United States, Canada, Argentina, and Italy. PATIENTS: Fifty-three white families composed of multiple members affected with AD, from whom DNA samples were obtained from 173 patients with AD whose conditions were diagnosed using established criteria and from 146 nondemented relatives. MAIN OUTCOME MEASURE: Presence of an APOE epsilon4 allele among affected family members. RESULTS: Using parametric methods, no evidence for linkage to the region spanned by the chromosome 12 markers could be detected if familial AD is assumed to arise from the same genetic locus in all 53 families. However, significant evidence for linkage was detected in the presence of locus heterogeneity using the admixture test (odds ratio, 15, 135:1). The estimated proportion of linked families within the 53 families examined varied between 0.40 and 0.65, depending on the genetic model assumed and APOE status. The precise location of the AD gene could not be determined, but includes the entire region suggested previously. Nonparametric linkage analysis confirmed linkage to chromosome 12 with the strongest evidence at D12S96 (P<.001). CONCLUSIONS: Our data provide independent confirmation of the existence of an AD susceptibility locus on chromosome 12 and suggest the existence of AD susceptibility genes on other chromosomes. Screening a larger set of families with additional chromosome markers will be necessary for identifying the chromosome 12 AD gene.
Authors: Mariet Allen; Claire Cox; Olivia Belbin; Li Ma; Gina D Bisceglio; Samantha L Wilcox; Chanley C Howell; Talisha A Hunter; Oliver Culley; Louise P Walker; Minerva M Carrasquillo; Dennis W Dickson; Ronald C Petersen; Neill R Graff-Radford; Steven G Younkin; Nilüfer Ertekin-Taner Journal: Neurobiol Aging Date: 2010-09-23 Impact factor: 4.673
Authors: Daniel W Hahs; Jacob L McCauley; Amy E Crunk; Lynne L McFarland; Perry C Gaskell; Lan Jiang; Susan H Slifer; Jeffery M Vance; William K Scott; Kathleen A Welsh-Bohmer; Stephanie R Johnson; Charles E Jackson; Margaret A Pericak-Vance; Jonathan L Haines Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2006-03-05 Impact factor: 3.568
Authors: Ekaterina Rogaeva; Yan Meng; Joseph H Lee; Yongjun Gu; Toshitaka Kawarai; Fanggeng Zou; Taiichi Katayama; Clinton T Baldwin; Rong Cheng; Hiroshi Hasegawa; Fusheng Chen; Nobuto Shibata; Kathryn L Lunetta; Raphaelle Pardossi-Piquard; Christopher Bohm; Yosuke Wakutani; L Adrienne Cupples; Karen T Cuenco; Robert C Green; Lorenzo Pinessi; Innocenzo Rainero; Sandro Sorbi; Amalia Bruni; Ranjan Duara; Robert P Friedland; Rivka Inzelberg; Wolfgang Hampe; Hideaki Bujo; You-Qiang Song; Olav M Andersen; Thomas E Willnow; Neill Graff-Radford; Ronald C Petersen; Dennis Dickson; Sandy D Der; Paul E Fraser; Gerold Schmitt-Ulms; Steven Younkin; Richard Mayeux; Lindsay A Farrer; Peter St George-Hyslop Journal: Nat Genet Date: 2007-01-14 Impact factor: 38.330
Authors: Richard Sherva; Clinton T Baldwin; Rivka Inzelberg; Badri Vardarajan; L Adrienne Cupples; Kathryn Lunetta; Abdalla Bowirrat; Adam Naj; Margaret Pericak-Vance; Robert P Friedland; Lindsay A Farrer Journal: J Alzheimers Dis Date: 2011 Impact factor: 4.472
Authors: Peter T Nelson; Yuriko Katsumata; Kwangsik Nho; Sergey C Artiushin; Gregory A Jicha; Wang-Xia Wang; Erin L Abner; Andrew J Saykin; Walter A Kukull; David W Fardo Journal: Acta Neuropathol Date: 2016-11-04 Impact factor: 17.088
Authors: R Mayeux; J H Lee; S N Romas; D Mayo; V Santana; J Williamson; A Ciappa; H Z Rondon; P Estevez; R Lantigua; M Medrano; M Torres; Y Stern; B Tycko; J A Knowles Journal: Am J Hum Genet Date: 2001-11-19 Impact factor: 11.025
Authors: Ping-I Lin; Eden R Martin; Carrie A Browning-Large; Donald E Schmechel; Kathleen A Welsh-Bohmer; P Murali Doraiswamy; John R Gilbert; Jonathan L Haines; Margaret A Pericak-Vance Journal: Neurogenetics Date: 2006-06-13 Impact factor: 2.660
Authors: J H Lee; R Mayeux; D Mayo; J Mo; V Santana; J Williamson; A Flaquer; A Ciappa; H Rondon; P Estevez; R Lantigua; T Kawarai; A Toulina; M Medrano; M Torres; Y Stern; B Tycko; E Rogaeva; P St George-Hyslop; J A Knowles Journal: Mol Psychiatry Date: 2004-11 Impact factor: 15.992
Authors: Joseph H Lee; Rong Cheng; Ekaterina Rogaeva; Yan Meng; Yaakov Stern; Vincent Santana; Rafael Lantigua; Martin Medrano; Ivonne Z Jimenez-Velazquez; Lindsay A Farrer; Peter St George-Hyslop; Richard Mayeux Journal: Neurogenetics Date: 2008-03-14 Impact factor: 2.660